Founded in 2015, WRS Therapeutics has developed a proprietary technology using microparticles coated with surfactants to overcome barriers to absorption of large molecules in the gastrointestinal system. Through in vitro and in vivo studies, the company has demonstrated the successful delivery of various large molecule drugs through the digestive system. WRS Therapeutics aims to secure seed financing in late 2016 to become the first to gain FDA approval for an oral biologic, positioning itself as a pioneer in the field of oral delivery of large molecules.